-

MedinCell’s Long-Acting Injectable to Fight Malaria Ready to Enter Regulatory Development

MedinCell and the project consortium members, IRD, IRSS and CIRDES, have successfully designed, tested, and confirmed with Unitaid the selection of the lead formulation. Regulatory preclinical activities are starting with the objective of a first clinical trial in 2023.

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell and the consortium members have conducted an in vivo proof of concept on cattle that showed a 3-month mosquitocidal effectiveness of an injectable long-acting formulation of Ivermectin based on the proprietary BEPO® technology.

The investigational product mdc-STM aims at reducing the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people.

Malaria remains one of the main health threats worldwide with more than 200 million people infected yearly.

In March 2020, global health agency Unitaid granted MedinCell with a $6.4 million subvention over three years to conduct the formulation and preclinical activities of the program.

mdc-STM benefits from synergies with other MedinCell’s programs based on Ivermectin all of them using different formulation and doses fitted to their specific indications.

Access the complete press release.

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.

www.medincell.com

Contacts

MedinCell
David Heuzé
Head of communication
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

MedinCell

BOURSE:MEDCL

Release Versions

Contacts

MedinCell
David Heuzé
Head of communication
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

More News From MedinCell

UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell’s partner Teva Pharmaceuticals shared today the following information: About UZEDY® 1-Month and 2-Month subcutaneous risperidone for schizophrenia Commercialized in the U.S. since May 2023 2024 sales: $117 million, Q1 2025 sales: $39 million, 2.6x increase compared to Q1 2024 Continuous growth of prescription: 2.8x increase compared to Q1 2024 Medincell receives mid- to high-single digit royalties on all sales and is eligible for...

Medincell and iM4TB Initiate Development of a Long-Acting Injectable Version of Macozinone, a Promising Investigational Tuberculosis Treatment

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL) : Prof. Stewart Cole, Chairman of the Board of iM4TB, said: “Long-acting injectable antiretroviral formulations have simplified, and radically improved HIV-AIDS treatment and we are confident that this will also be the case with TB. Being highly potent due to its ideal physicochemical properties, Macozinone is a perfect candidate for the LAI approach. We are thrilled to partner with Medincell and to harness their gro...

Medincell Increases the Amount Allocated to the Liquidity Contract with Rothschild Martin Maurel

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: In order to accompany the increase in the volumes of shares traded daily, Medincell (Paris:MEDCL) signed on April 11, 2025 an amendment to the Liquidity Agreement entered into with Rothschild Martin Maurel on September 10, 2024, in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, Commission Delegated Regulation (EU) 2016/908 of February 26, 2016, Articles L. 225-...
Back to Newsroom